HSBC Holdings
PSTX

HSBC Holdings’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

HSBC Holdings’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58,530
Closed -$166K – 3267
2024
Q3 		$166K Buy
58,530
+1,914
+3% +$5.92K ﹤0.01% 2684
2024
Q2 		$156K Sell
56,616
-119
-0.2% -$325 ﹤0.01% 2636
2024
Q1 		$181K Buy
56,735
+7,743
+16% +$25.8K ﹤0.01% 2717
2023
Q4 		$161K Buy
48,992
+55
+0.1% +$142 ﹤0.01% 2523
2023
Q3 		$116K Buy
+48,937
New +$103K ﹤0.01% 2533

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HSBC Holdings's PSTX Position: Q4 2024 in Review

HSBC Holdings sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 58,530 shares — an estimated $166K sold.

HSBC Holdings first reported a position in PSTX in Q3 2023 and held it in 5 quarters. The position peaked at $181K in Q1 2024. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • HSBC Holdings reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • HSBC Holdings sold 58,530 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $166K.
  • HSBC Holdings first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2023 and held it in 5 quarters.
  • HSBC Holdings's Poseida Therapeutics, Inc. Common Stock position peaked at $181K in Q1 2024.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on HSBC Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.